AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

Credit: crystal light/Shutterstock. On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American ...

AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

A PHASE IIa clinical trial has investigated tozorakimab, an anti-IL-33 monoclonal antibody, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) and chronic bronchitis, ...

The Key Chronic Obstructive Pulmonary Disease Companies in the market include - Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo ...

Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) ...

Soluble ST2 (sST2), a decoy receptor of IL-33, is a prognostic serum biomarker for heart failure (HF). Here, we evaluated the impact of tozorakimab, an IL-33-neutralizing monoclonal antibody, on ...